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Structural biology
X-ray crystallographyThree-dimensional macromolecular structures shed critical light on biological mechanism and facilitate
development of small molecule inhibitors. Clinical success of raltegravir, a potent inhibitor of HIV-1 integrase,
demonstrated the utility of this viral DNA recombinase as an antiviral target. A variety of partial integrase
structures reported in the past 16 years have been instrumental and very informative to the ﬁeld.
Nonetheless, because integrase protein fragments are unable to functionally engage the viral DNA substrate
critical for strand transfer inhibitor binding, the early structures did little to materially impact drug
development efforts. However, recent results based on prototype foamy virus integrase have fully reversed
this trend, as a number of X-ray crystal structures of active integrase-DNA complexes revealed key
mechanistic details and moreover established the foundation of HIV-1 integrase strand transfer inhibitor
action. In this review we discuss the landmarks in the progress of integrase structural biology during the past
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The integration of the linear viral DNA (vDNA) made during
reverse transcription into a cell chromosome is one of many essentialsteps in the retroviral lifecycle. Integration is orchestrated by the viral
integrase (IN) protein, which recognizes and acts upon the vDNA
ends, catalyzing two sequential endonucleolytic reactions. Initially, IN
hydrolyzes a phosphodiester at one or both 3′ ends adjacent to
invariant CA sequences to unveil reactive adenosine 3′-OH groups.
Then, after ﬁnding a suitable target site on chromatin in the cell
nucleus, IN carries out DNA strand transfer by using the 3′-hydroxyls
to cut phosphodiester bonds on opposing strands of target DNA
(tDNA) across the major groove with deﬁned spacing, which at the
same time joins the vDNA ends to the chromosome. The resulting
DNA recombination intermediate, with unjoined vDNA 5′ ends
abutting single stranded tDNA gaps, is repaired by host cell machinery
195X. Li et al. / Virology 411 (2011) 194–205to yield the integrated provirus ﬂanked by the sequence duplication of
the double stranded tDNA cut. See Engelman (2010) for a recent
overview of retroviral DNA integration.
Seminal work in the late 1980s–early 1990s revealed recombinant
IN proteins possess divalent metal ion- (Mn2+ or Mg2+) dependent 3′
processing and DNA strand transfer activities in vitro (Bushman et al.,
1990; Craigie et al., 1990; Katz et al., 1990; Katzman et al., 1989; Pahl
and Flügel, 1993; Sherman and Fyfe, 1990). From this onset it was
evident the 288-residue HIV-1 IN was refractory to structural biology
approaches due to relatively poor protein solubility, limited at ~1 mg/
ml (Hickman et al., 1994; Jenkins et al., 1996). In work designed to test
if HIV-1 IN worked as an enzyme, Chow et al. (1992) discovered a
novel in vitro function, disintegration, whereby substrates modeling
the DNA strand transfer reaction product could be separated into viral
and tDNA components. Although disintegration activity is probably
not relevant to virus infection, it was a boon for dissecting IN
functionality.
Retroviral IN proteins contain three or four sub-domains of
variable evolutionary conservation (Fig. 1). The catalytic core domain
(CCD) harbors a D,D-35-E amino acid sequence motif conserved
among retroviral and retrotransposon INs as well as some bacterial
transposase proteins (Engelman and Craigie, 1992; Kulkosky et al.,
1992), and the invariant Asp and Glu residues (Asp64, Asp116, and
Glu152 for HIV-1) were critical for catalysis of 3′ processing, DNA
strand transfer (Drelich et al., 1992; Kulkosky et al., 1992), and
disintegration activities (Engelman and Craigie, 1992; Leavitt et al.,
1993; van Gent et al., 1992). Isolated CCDs from HIV-1 (Bushman
et al., 1993) and avian sarcoma-leukosis virus (ASLV) (Kulkosky et al.,
1995) IN proteins lacked appreciable 3′ processing and DNA strand
transfer activities, yet importantly were proﬁcient at disintegration.
Mixtures of certain defective HIV IN N-terminal domain (NTD) and C-
terminal domain (CTD) deletionmutant proteinsmoreover supported
3′ processing and DNA strand transfer activities, suggesting that the
protein likely functioned as a multimer and that individual IN chains
could share their domains within the functional complex (Ellison
et al., 1995; Engelman et al., 1993; van Gent et al., 1993). Additional
protein mixing experiments yielded overall similar domain organiza-
tions for Gammaretrovirus (Jonsson et al., 1996) and Spumavirus (Pahl
and Flügel, 1995) INs (Fig. 1). Despite frustrationswith full-length INs,
these studies established the validity of structural approaches of
isolated protein domains.
Early analyses of HIV-1 IN activities tended not to distinguish DNA
strand transfer reaction products that formed from the integration of
a single vDNA end into one strand of tDNA versus the concertedFig. 1. Domain organization and secondary structural elements of representative IN protein
terminal 38 residues of the ASLV Gag-Pol precursor (parentheses) is cleaved during virus m
residue protein are detected in virions (Alexander et al., 1987). Secondary structural element
2010) and ASLV CCD-CTD (Yang et al., 2000) and PFV intasome (Hare et al., 2010a) crystal st
terminal extension domain; NTD, N-terminal domain; CCD, catalytic core domain; and CTD, C
retroviral INs are coded based on chemical property: electronegative, red; electropositive,
(Jaskolski et al., 2009).integration of a pair of vDNAs ends into opposing tDNA strands with
deﬁned spacing, as occurs during virus infection (Bushman and
Craigie, 1991). Reaction modiﬁcations that included relatively long
vDNA substrates signiﬁcantly improved concerted HIV-1 IN activity
(Faure et al., 2005; Li and Craigie, 2005; Sinha and Grandgenett,
2005; Sinha et al., 2002), important advances for addressing
physiologically relevant IN-to-vDNA stoichiometry. The following
nomenclature adopts terminology from the bacteriophage Mu
transposition ﬁeld, where earlier work with MuA transposase
established DNA cutting and joining reactions analogous to those
that occur during retroviral integration and salient nucleoprotein
reaction intermediates (reviewed in Chaconas, 1999). A tetramer of
IN engages two vDNA ends in an initial stable synaptic complex
(SSC), which is converted to the cleaved donor complex (CDC) by 3′
processing. Subsequent tDNA binding yields the target capture
complex (TCC), which morphs into the strand transfer complex
(STC) after vDNA 3′ end joining (Bera et al., 2009; Kotova et al., 2010;
Li et al., 2006; Pandey et al., 2007). These data, combined with prior
solution-based measurements of ASLV IN functionality (Bao et al.,
2003), helped clarify that an IN tetramer bound to two vDNA ends
comprised the functional unit of retroviral integration. This basic
nucleoprotein complex is referred to as the intasome (Chen et al.,
1999; Hare et al., 2010a; Wei et al., 1997).
To date one HIV-1 IN inhibitor, raltegravir (RAL), has been licensed
for patient use (Summa et al., 2008). Because RAL and similar
compounds selectively block DNA strand transfer activity, the drugs
are collectively known as IN strand transfer inhibitors (INSTIs)
(McColl and Chen, 2010). Pipeline INSTIs were shown to bind IN-
vDNA complexes with signiﬁcantly higher afﬁnity than free HIV-1 IN
protein (Espeseth et al., 2000; Grobler et al., 2002), indicating that a
vDNA-dependent IN conformational change(s) was critical for high
afﬁnity binding or the drugs interacted directly with a vDNA
component (Alian et al., 2009; McColl and Chen, 2010). Elegant
dissection of individual sequence elements highlighted roles for the
vDNA end and in particular, the 3′ adenosine, in INSTI binding (Dicker
et al., 2007; Langley et al., 2008).
Like any other step of viral replication, integration seems to depend
on a plethora of cellular co-factors (reviewed in Turlure et al., 2004 and
VanMaele et al., 2006). One HIV-1 IN-binding protein in particular, lens
epithelium-derived growth factor (LEDGF) (Cherepanov et al., 2003),
has proven central for preferential targeting of lentiviral integration to
active transcription units (reviewed in Engelman and Cherepanov,
2008 and Poeschla, 2008). LEDGF interacts with HIV-1 IN via a small
evolutionarily-conserved IN binding domain (IBD) (Cherepanov et al.,s. Interdomain linker and C-terminal tail region lengths are indicated above lines; the
orphogenesis to yield the mature 286-residue IN, though small amounts of the 323-
s (line, alpha helix; arrow, beta strand) from the HIV-1 intasomemodel (Krishnan et al.,
ructures shown underneath each drawing are numbered according to domain (NED, N-
-terminal domain). Domains are color-coded for simplicity; residues conserved among
blue; sulfur-containing, yellow. Proteins aligned based on the start of NTD sequences
196 X. Li et al. / Virology 411 (2011) 194–2052004; Vanegas et al., 2005). On the IN side, the CCD is essential and
minimally sufﬁcient to bind the host factor, although the NTD is
required for high afﬁnity interaction (Maertens et al., 2003). Recom-
binant LEDGF protein furthermore displayed favorable solubility at
isotonic salt concentration and because LEDGF-HIV-1 IN complex
solubility mimicked that of LEDGF (P. Cherepanov and A. Engelman,
unpublished observations; Busschots et al., 2005), the host factor has
become a valuable lentiviral IN structural biology tool (Cherepanov
et al., 2005a; Gupta et al., 2010; Hare et al., 2009a,b;Michel et al., 2009).
The start: Individual IN domain structures
Though it became clear the CCD was a more tractable target than
full-length HIV-1 IN (Hickman et al., 1994), the isolated domain was
relatively insoluble. In an elegant approach, Jenkins et al. discovered
the F185K mutation, which dramatically increased solubility
(Jenkins et al., 1995) and in turn enabled crystallization and the
determination of the X-ray structure of the HIV-1 CCD (Dyda et al.,
1994) (Fig. 2A). This landmark study revealed that retroviral INs
belonged to the large superfamily of polynucleotidyl transferases,
typiﬁed by RNase H, and conﬁrmed that the invariant carboxylates
of the IN D,D-35-E motif indeed comprise the active site (Dyda et al.,
1994). The crystallographic asymmetric unit harbored a dimer with
an extensive interface, and similar dimeric interfaces were observed
in the subsequent crystal structures that contain a retroviral IN CCD
(see Table 1 for a comprehensive list of IN structures). The active
sites within the dimer were separated from one another by
approximately 35 Å, a distance seemingly incompatible with
integration across a major groove in tDNA (Dyda et al., 1994),
suggesting the active site arrangement in the CCD dimer may not
account for the concerted integration of two HIV-1 DNA ends. Recent
crystallographic analysis of tetrameric prototype foamy virus (PFV)
IN assembled on a pair of vDNA ends conﬁrmed this early contention
(Hare et al., 2010a) (see below). The polynucleotidyl transferase
superfamily has since expanded to include a variety of nucleic acid
metabolizing enzymes such as DNA transposase proteins and
Argonaute, the nuclease component of the RISC mRNA silencing
complex (Nowotny, 2009). Despite its utility to structural biology,
the F185K change rendered HIV-1 nonviable due to defects at
integration, particle assembly, and reverse transcription (Jenkins
et al., 1996). However, substituting Phe185 for His also yielded a
crystallizable HIV-1 IN CCD construct (Bujacz et al., 1996a) without
associated lethal defects in viral replication (Engelman et al., 1997).
Highlighting the importance of Phe185 alterations for structural
biology, all CCD-containing HIV-1 IN crystal structures harbor either
the F185K or F185H change (Table 1).
Work conducted at around the same time elucidated the X-ray
structure of the ASLV IN CCD at 1.7 Å resolution (Bujacz et al., 1995)Fig. 2. Structures of individual HIV-1 IN domains. (A) X-ray crystal structure (PDB code 1ITG
sticks); the third member of the DDE catalytic triad, Glu152, was undecipherable in this ini
visible in this orientation. Dashed lines indicate disordered gaps in polypeptide chains. (B) C
ﬁve-stranded beta barrel. (C) HIV-1 IN NTD monomer from PDB code 1WJC. Highlighted are
(grey sphere). Visualized IN residue termini are indicated in panels B and C.(Table 1). Importantly, all three active site D,D-35-E carboxylates
were ordered in this structure. A ﬂurry of additional HIV-1 (Goldgur
et al., 1999, 1998; Greenwald et al., 1999; Maignan et al., 1998;
Molteni et al., 2001) and ASLV (Bujacz et al., 1997, 1996b;
Lubkowski et al., 1999, 1998a, 1998b) CCD structures quickly
followed suit, which in some instances improved resolution and
suggested binding sites for preclinical catalytic (Goldgur et al., 1999;
Lubkowski et al., 1998b) or allosteric (Molteni et al., 2001) inhibitors
and/or catalytic metal ion co-factors (Goldgur et al., 1999, 1998;
Maignan et al., 1998). Though important advances, these studies
nonetheless fell short of achieving complete active site pictures
because they lacked a critical component, the vDNA end substrate.
Crystal structures of PFV (Réty et al., 2010; Valkov et al., 2009) and
bovine immunodeﬁciency virus (BIV) (Yao et al., 2010) IN CCDs have
been reported more recently (Table 1).
NTD and CTD structures were initially solved using NMR spectros-
copy. The HIV-1 CTD folds into a 5-stranded beta barrel that
interestingly resembles a Src homology 3 (SH3) domain (Eijkelenboom
et al., 1995, 1999; Lodi et al., 1995) (Fig. 2B). The CTD was initially
described as a likely DNA-binding domain (Engelman et al., 1994; Vink
et al., 1993; Woerner et al., 1992; Woerner and Marcus-Sekura, 1993)
and although SH3 domains most often interact with Pro-rich regions in
proteins (Kaneko et al., 2008), some, such as Sulfolobus solfatarius
Sso7d, are indeed known to bind DNA (Baumann et al., 1994). Solution
structures of the NTDs from HIV-1 (Cai et al., 1997) and HIV-2
(Eijkelenboom et al., 1997, 2000) INs revealed 3-helical bundles
stabilized through binding a Zn2+ ion (Fig. 2C). The metal had been
shown to be an important IN co-factor (Lee and Han, 1996; Lee et al.,
1997; Zheng et al., 1996) and the structures conﬁrmed that the
invariant His and Cys residues (Fig. 1), previously implicated in Zn2+
binding (Burke et al., 1992; Bushman et al., 1993) serve to tetrahedrally
coordinate the ion (Fig. 2C). Although the HIV-1 NTD and CTD
constructs were dimeric (Cai et al., 1997; Eijkelenboom et al., 1995,
1999; Lodi et al., 1995), the dimer interfaces were not observed in later
crystal structures (J.C. Chen et al., 2000; Z. Chen et al., 2000; Hare et al.,
2010a; Yang et al., 2000). Hence, the relevance of such homomeric
dimerization among CTD or NTD constructs is not clear.
Structures of 2-domain IN fragments hint at multimer
functionality
Having solved the structure of each canonical IN domain in
isolation, it behooved investigators to determine how they meshed
together within active IN complexes (see Chiu and Davies, 2004
and Jaskolski et al., 2009 for recent reviews). The combination of
ﬁve solubility-enhancing mutations (C56S, W131D, F139D, F185K,
and C280S) enabled full-length HIV-1 IN to be concentrated to
N12 mg/ml but did not yield high-quality crystals (J.C. Chen et al.,) highlighting the common CCD dimer and active site residues Asp64 and Asp116 (red
tial structure. Only one of two Lys185 solubility-enhancing substitutions (blue stick) is
TD NMR structure (PDB code 1IHV) revealed a dimer, with each monomer folded into a
Zn-coordinating residues His12, His16, Cys 40, and Cys43 as well as the bound Zn2+ ion
Table 1
Retroviral IN structures reported in the RCSB Protein Data Bank.
Virusa Domain(s); mutations(s)b Ligand(s)c Res.d PDB codee Ref.f
HIV-1 CCD; F185K cacodylate 2.3 1ITG 1
HIV-1 CTD NA 1IHV 2
HIV-1 CCD; F185H 2.6 2ITG 3
HIV-1 NTD Zn NA 1WJC, 1WJD 4
HIV-1 NTD Zn NA 1WJA, 1WJB 4
HIV-1 NTD; H12C Cd NA 1WJE, 1WJF 5
HIV-1 CCD; W131E/F185K 1.95 1BIS 6
HIV-1 CCD; W131E/A133G/F185K Mg 2.5 1BIU 6
HIV-1 CCD; C56S/F185K cacodylate 1.95 1BIZ 6
HIV-1 CCD; F185H Mg 2.0 1BL3 7
HIV-1 CCD; F185H cacodylate 2.2 1BHL 7
HIV-1 CCD; F185H 2.5 1BI4 7
HIV-1 CCD; F185K cacodylate/sulfate 1.7 1B9D 8
HIV-1 CCD; G149A/F185K cacodylate/sulfate 2.02 1B92 8
HIV-1 CCD; G140A/G149A/F185K cacodylate/sulfate 1.7 1B9F 8
HIV-1 CCD; W131E/A133G/F185K Mg/5CITEP 2.1 1QS4 9
HIV-1 CTD NA 1QMC 10
HIV-1 CCD; C56S/W131D/F139D/F185K Cd/sulfate 1.6 1EXQ 11
HIV-1 CCD/CTD; C56S/W131D/F139D/F185K/C280S CHAPS 2.8 1EX4 11
HIV-1 NTD/CCD; W131D/F139D/F185K Zn/phosphate 2.4 1K6Y 12
HIV-1 CCD; F185K TTA/sulfate 1.7 1HYV 13
HIV-1 CCD; F185K TTO/sulfate 2.3 1HYZ 13
HIV-1 CCD; F185K LEDGF/phosphate 2.02 2B4J 14
HIV-1 CCD; F185K Ca/723 2.0 3LPT 15
HIV-1 CCD; F185K Ca/976 1.95 3LPU 15
HIV-1 CCD; C56S/W131D/W139D/F185H sulfate 1.4 3L3U 16
HIV-1 CCD; C56S/W131D/W139D/F185H Cd/sucrose/sulfate 2.0 3L3V 16
HIV-2 NTD Zn NA 1E0E 17
HIV-2 NTD/CCD Zn/LEDGF/Mg 3.2 3F9K 18
SIV CCD/CTD; F185H 3.0 1C6V 19
MVV NTD/CCD Zn/LEDGF 3.28 3HPG 20
MVV NTD/CCD Zn/LEDGF/phosphate 2.64 3HPH 20
BIV CCD nitrate 2.45 3KKR 21
BIV CCD acetate 2.2 3KKS 21
ASLV CCD HEPES 1.7 1ASU 22
ASLV CCD 2.2 1ASV 22
ASLV CCD HEPES 1.8 1ASW 22
ASLV CCD Mg/HEPES 1.7 1VSD 23
ASLV CCD HEPES 2.2 1VSE 23
ASLV CCD Mn/HEPES 2.05 1VSF 23
ASLV CCD Zn/HEPES 1.95 1VSH 24
ASLV CCD Ca/HEPES 2.2 1VSI 24
ASLV CCD Cd/HEPES 2.1 1VSJ 24
ASLV CCD Mn/Y3 1.9 1A5V 25
ASLV CCD Y3 2.0 1A5W 25
ASLV CCD Y3 1.9 1A5X 25
ASLV CCD; D64N 2.2 1VSK 26
ASLV CCD; D64N Zn 2.2 1VSL 26
ASLV CCD 2.15 1VSM 26
ASLV CCD HEPES 1.02 1CXQ 27
ASLV CCD citrate 1.42 1CXU 27
ASLV CCD; D64N citrate/sulfate 1.2 1CZ9 27
ASLV CCD HEPES 1.06 1CZB 27
ASLV CCD/CTD; F199K 2.53 1C0M 28
ASLV CCD/CTD; F199K 3.1 1C1A 28
PFV CCD Mg 2.2 3DLR 29
PFV CCD; I127M/I227M/L253M Mn 2.06 2X6N 30
PFV CCD; I127M/I227M/L253M Mg 2.29 2X6S 30
PFV CCD; I127M/I227M/L253M 2.34 2X74 30
PFV CCD 2.0 2X78 30
PFV Full-length Zn/vDNA 3.25 3L2Q 31
PFV Full-length Zn/vDNA/Mg 2.88 3L2R 31
PFV Full-length Zn/vDNA/Mn 2.55 3OY9 31, 32
PFV Full-length Zn/vDNA/Mg/RAL 2.65 3OYA 31, 32
PFV Full-length Zn/vDNA/Mg/EVG 3.15 3L2U 31
PFV Full-length Zn/vDNA/Mn/RAL 3.2 3L2V 31
PFV Full-length Zn/vDNA/Mn/EVG 3.2 3L2W 31
PFV Full-length Zn/vDNA/Mg/tDNA 2.81 3OS0 33
PFV Full-length Zn/vDNA/Mg/tDNA 2.97 3OS1 33
PFV Full-length Zn/vDNA/tDNA 3.32 3OS2 33
PFV Full-length Zn/vDNA/Mg/MK-2048 2.54 3OYB 32
PFV Full-length Zn/vDNA/Mg/PICA 2.66 3OYC 32
PFV Full-length Zn/vDNA/Mg/GS-9160 2.54 3OYD 32
PFV Full-length Zn/vDNA/Mg/compound2 2.74 3OYE 32
PFV Full-length Zn/vDNA/Mg/L,870810 2.51 3OYF 32
(continued on next page)
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Table 1 (continued)
Virusa Domain(s); mutations(s)b Ligand(s)c Res.d PDB codee Ref.f
PFV Full-length Zn/vDNA/Mg/compound1 2.56 3OYG 32
PFV Full-length Zn/vDNA/Mg/MK-0536 2.74 3OYH 32
PFV Full-length; S217Q Zn/vDNA/Mn 2.72 3OYI 32
PFV Full-length; S217Q Zn/vDNA/Mg/MK-2048 2.68 3OYJ 32
PFV Full-length; S217H Zn/vDNA/Mn 2.72 3OYK 32
PFV Full-length; S217H Zn/vDNA/Mg/MK-2048 2.54 3OYL 32
PFV Full-length; N224H Zn/vDNA/Mn 2.02 3OYM 32
PFV Full-length; N224H Zn/vDNA/Mg/MK-2048 2.68 3OYN 32
a HIV-1, human immunodeﬁciency virus type 1; HIV-2, human immunodeﬁciency virus type 2; SIV, simian immunodeﬁciency virus; MVV, maedi-visna virus; BIV, bovine
immunodeﬁciency virus; ASLV, avian sarcoma-leukosis virus; PFV, prototype foamy virus.
b CCD, catalytic core domain; NTD, N-terminal domain; CTD, C-terminal domain.
c 5CITEP, 1-(5-chloroindol-3-yl)-3-hydroxy-3-(2 h-tetrazol- 5-yl)-propenone; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate; TTA, tetraphenyl-
arsonium; TTO, (3,4-dihydroxy-phenyl)-triphenyl-arsonium; Y3, 4-acetylamino-5-hydroxynaphthalene-2,7-disulfonic acid; 723, (6-chloro-2-oxo-4-phenyl-1,2-dihydroquinolin-
3-yl)acetic acid; 976, (2 S)-2-(6-chloro-2-methyl-4-phenylquinolin-3-yl)pentanoic acid; LEDGF, lens epithelium-derived growth factor; vDNA, viral DNA; RAL, raltegravir; EVG,
elvitagravir; tDNA, target DNA.
d Res, resolution in Å. NA, not applicable, as structure was solved by NMR.
e PDB, protein data base. Two codes are listed for studies that reported collective and minimized average NMR structures.
f Ref, references: 1 – Dyda et al., 1994; 2 – Lodi et al., 1995; 3 – Bujacz et al., 1996a; 4 – Cai et al., 1997; 5 – Cai et al., 1998; 6 – Goldgur et al., 1998; 7 – Maignan et al., 1998; 8 –
Greenwald et al., 1999; 9 – Goldgur et al., 1999; 10 – Eijkelenboom et al., 1999; 11 – J.C. Chen, et al., 2000; 12 – Wang et al., 2001; 13 – Molteni et al., 2001; 14 – Cherepanov et al.,
2005a; 15 – Christ et al., 2010; 16 –Wielens et al., 2010; 17 – Eijkelenboom et al., 2000; 18 – Hare et al., 2009b; 19 – Z. Chen, et al., 2000; 20 –Hare et al., 2009a; 21 – Yao et al., 2010;
22 – Bujacz et al., 1995; 23 – Bujacz et al., 1996b; 24 – Bujacz et al., 1997; 25 – Lubkowski et al., 1998b; 26 – Lubkowski et al., 1998a; 27 – Lubkowski et al., 1999; 28 – Yang et al., 2000;
29 – Valkov et al., 2009; 30 – Réty et al., 2010; 31 – Hare et al., 2010a; 32 – Hare et al., 2010b; 33 – Maertens et al., 2010.
198 X. Li et al. / Virology 411 (2011) 194–2052000). However crystals of a CCD-CTD construct containing the
aforesaid mutations diffracted to 2.8 Å resolution, and the resulting
structure revealed asymmetric alpha helices connecting CTDs to the
canonical CCD dimer (J.C. Chen et al., 2000) (Fig. 3A). Reports of
two other CCD-CTD structures at about the same time interestingly
revealed different arrangements among protein domains. For
simian immunodeﬁciency virus (SIV), a sole CTD could be observed
in closer proximity to the CCD dimer (Z. Chen et al., 2000) (Fig. 3B);
due to the lack of CCD-CTD interdomain linker electron density in
these crystals, alternative spatial interpretations were possible
(Wang et al., 2001). In the case of ASLV CCD-CTD crystals, variable
linker connections yielded still different CTD positions (Yang et al.,
2000) (Fig. 3C). Comparing the results, it became clear that crystal
packing interactions likely impacted interdomain linker ﬂexibility
of these construct. Hence, none of the resulting relative domain
orientations could be generalized. Consistent with this notion,
Arg199, which as part of α6 aligns just 3 residues from the CCD
terminus (Figs. 1 and 3A), became hypersensitive to chemical
modiﬁcation when full-length HIV-1 IN bound vDNA (Zhao et al.,
2008). In hindsight, interdomain linker changes that occur upon
substrate binding (Hare et al., 2010a; Zhao et al., 2008) likely
limited the use of CCD-CTD structures to predict vDNA binding
platforms.Fig. 3. Two-domain X-ray crystal structures revealed variable CCD-CTD arrangements among
eachmonomer within the canonical CCD dimer. Arg199 side chains are indicated by blue stic
dimer as compared to the HIV-1 structure in panel A. (C) The ASLV 2-domain structure revea
for similar CCD dimer sizes, each positioned as in Fig. 2A. Red sticks indicate catalytic DDEThree solubilizing mutations (W131D, F139D and F185K) enabled
NTD-CCD fragment crystallization and structure reﬁnement to 2.4 Å
resolution (Fig. 4A) (Wang et al., 2001). Considering growing
evidence for the relevance of an IN tetramer, the NTD-CCD
crystallographic asymmetric unit interestingly harbored a dimer of
dimers (Fig. 4A, green/yellow and cyan/yellow). Due to disorder of the
NTD-CCD linkers and packing in these crystals, it was impossible to
unambiguously assign which NTD belonged to which CCD (Hare et al.,
2009b; Jaskolski et al., 2009). However, the interface between
interacting dimers included a pair of NTDs, and the assignment of
these NTDs was conﬁrmed by later studies with divergent retroviral
INs (Hare et al., 2009a,b). When describing the IN tetramer, it helps to
differentiate between two types of structurally and functionally
distinct subunits. The inner subunits (colored green and cyan in Fig. 4)
interact via intermolecular NTD–CCD interfaces. The outer subunits
(yellow) do not have a clear role in tetramer formation, and their
function has not been clariﬁed to-date. The interaction between inner
and outer subunits within each half of the tetramer is mediated by the
canonical CCD–CCD dimerization interface. The key contacts in the
NTD–CCD interaction, later conﬁrmed to be important for IN
tetramerization (Berthoux et al., 2007; Hare et al., 2009a; McKee
et al., 2008), included hydrophobic interactions mediated by NTD
residue Tyr15 and salt-bridges between NTD residues Glu11 andretroviral INs. (A) The HIV-1 structure (PDB code 1EX4) unveiled CTDs extending from
k. (B) SIV structure (PDB code 1C6V) showing a single CTD in closer proximity to its CCD
led two CTDs off kilter from the 2-fold CCD dimer symmetry axis. The drawing is scaled
triads; dashed lines, disordered gaps.
Fig. 4. Intermolecular NTD–CCD interactions among different multidomain IN crystal structures. (A) The dimer of dimers observed in the HIV-1 IN NTD-CCD crystallographic
asymmetric unit (PDB code 1K6Y) (Wang et al., 2001). Inner monomers are painted green and cyan; outer monomer (yellow) interactions are intradimer with partners connected
via canonical CCD interfaces. Interdimer NTC (green)–CCD (cyan) contact residues are shown in the lower panel, with salt bridges between ionic side chains highlighted by red
dashes. Interactions for other highlighted residues are mediated through polypeptide backbone atoms. (B) TheMVV IN NTD-CCD structure from PDB code 3HPH (Hare et al., 2009a),
oriented and labeled as in panel A. LEDGF IBDs were omitted for clarity. (C) TheMn-bound PFV intasome (PDB code 3OY9) (Hare et al., 2010a,b) oriented 45° to the right and 90° into
the page with respect to panels A and B to highlight interactions between the green NTD and cyan CCD. DNAmolecules were omitted for clarity. Side chains of DDE catalytic triads are
shown as red sticks in upper panels; secondary elements in lower panels based on Fig. 1; grey spheres, Zn atoms.
199X. Li et al. / Virology 411 (2011) 194–205Asp25 and CCD residues Lys186 and Lys188, respectively (Fig. 4A,
lower panel; see below for further discussion).
Co-crystal structures of IN and LEDGF fragments
An initial NMR structure of the LEDGF IBD revealed a dyad helix-
loop-helix PHAT (pseudo HEAT repeat analogous topology) fold
(Cherepanov et al., 2005b) and subsequent co-crystallization with
HIV-1 CCD/F185K revealed the essential portion of the virus-host
factor interface (Cherepanov et al., 2005a). The tip of a ﬁnger-like IBD
structure interacted with a small patch formed at the CCD dimer
interface. Symmetry of the dimeric CCD construct allowed binding of
two IBD molecules, resulting in IN:LEDGF stoichiometry of 1:1. LEDGF
residues Ile365, Asp366, Phe406, and Val408, identiﬁed earlier as
critical for the interaction with HIV-1 IN (Cherepanov et al., 2005b),
were involved in contacts with IN. In particular Asp366 made a
bidentate H bond to main chain amides of Glu170 and His171. The
structure reﬁned at 2.0 Å resolution played an essential role in the
recent design of competitive inhibitors of the HIV-1 IN–LEDGF
interaction, which bind to the viral protein by mimicking the H
bonding and hydrophobic functions of LEDGF residues Asp366 and
Ile365, respectively (Christ et al., 2010).
More recently, co-crystal structures of NTD-CCD constructs from
HIV-2 and maedi-visna virus (MVV) INs bound to the LEDGF IBD
elucidated what is likely the complete lentiviral IN–LEDGF interface
(Hare et al., 2009a,b). The NTD contributes electronegative residues
situated on its α1, which interact with a positively charged patch on
the side of the IBD structure formed by Lys401, Lys402, and Arg405.Although not essential for the HIV-1 IN–LEDGF interaction, the
charge–charge interface makes a substantial difference to its apparent
afﬁnity (Hare et al., 2009b). The ﬂexibility of the NTD-CCD connecting
regions allowed the NTD to participate in the interaction with the IBD
engaged to the same or another CCD dimer (Hare et al., 2009a,b). The
assemblies observed in the MVV structures could be interpreted as
dimers-of-dimers, providing composite LEDGF binding platforms
consisting of CCDs from one IN dimer and an NTD from the opposing
one (Hare et al., 2009a). Because LEDGF stimulates HIV-1 IN
tetramerization (Hare et al., 2009a; McKee et al., 2008), it seems
likely that the topology observed in the MVV structures is relevant.
Importantly, IN multimer arrangements in the MVV NTD-CCD
structures were similar to those previously observed in the structure
of the isolated HIV-1 IN NTD-CCD construct (Wang et al., 2001) and
revealed four independent dimer–dimer interfaces. Despite consid-
erable differences in mutual dimer orientations within the tetramers,
they were all formed through NTD–CCD interactions across the
dimer–dimer interface (Fig. 4B). Results of mutagenesis experiments
moreover proved the functional relevance of these intermolecular
interactions in in vitro integration assays and during HIV-1 infection
(Hare et al., 2009a). These data unveiled the structural basis for prior
observations that the HIV-1 IN NTD functioned in trans to the CCD
(Ellison et al., 1995; Engelman et al., 1993) and furthermore extended
the relevance of these ﬁndings to the context of virus infection. Of
note the analogous NTD–CCD interactions in the HIV-2 IN NTD-CCD–
IBD crystal structure formed intramolecularly, suggesting that
different NTDs might sequentially occupy the same niche during
functional intasome assembly (Hare et al., 2009b). The simplicity of
Fig. 5. Crystal structure of the active PFV intasome. (A) The crystallographic
asymmetric unit housed a dimer of IN bound to a single DNA molecule (PDB code
3L2Q) (Hare et al., 2010a). The non-transferred DNA strand is painted orange whereas
the transferred strand terminating in dAOH is magenta. (B) The intasome structure,
formed by duplication, C2 symmetry rotation, and merger of the panel A structure,
with the second DNA-bound monomer painted cyan. Other labeling is the same as in
Figs. 1 and 3.
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pairs that partially restored wild-type function in vitro and during
HIV-1 infection (Hare et al., 2009b).
The long-awaited breakthrough: X-ray crystal structure of the
functional intasome
Applied to structural biology of retroviral integration, the validity
of “shotgun” approaches is limited because full-length IN is required
to functionally engage vDNA substrates. Moreover, the urgent need
for understanding the mode of INSTI action necessitated work with
active IN-vDNA complexes (Hare et al., 2010a). X-ray crystallogra-
phy of active intasomes could only be approached using biochemical
systems that supported efﬁcient integration of relatively short
oligonucleotide mimics of vDNA ends. Unfortunately, HIV-1 con-
certed integration assays primarily relied on vDNA substrates of
several hundred bp (Carteau et al., 1999; Goodarzi et al., 1995;
Hindmarsh et al., 1999; Li and Craigie, 2005; Sinha and Grandgenett,
2005; Sinha et al., 2002), a mystery that remains unexplained today.
In principle, HIV-1 IN reactions containing relatively high concen-
trations of oligonucleotide vDNA substrate support concerted
integration in a LEDGF-dependent manner, yet very high levels of
single-end integration persist even under optimal in vitro conditions
(Hare et al., 2009b). Moloney murine leukemia virus IN integrated
short vDNA substrates in concerted fashion with reasonable
efﬁciency (Craigie et al., 1990; Yang and Roth, 2001), though
relatively poor solubility dissuaded extensive structural efforts with
this protein. Unlike the situation with transposases (Baus et al.,
2005; Davies et al., 2000), there seemed to be no trivial way to select
for a hyperactive mutant of a retroviral IN. A search for an IN protein
that could be naturally more amenable to in vitro experimentation
and crystallography eventually lead to the ortholog from PFV.
Recombinant PFV IN is remarkably soluble and could be concentrat-
ed to over 10 mg/ml in detergent-free buffers containing just 0.2 M
NaCl (Delelis et al., 2008; Valkov et al., 2009). Even more
impressively, the enzyme almost exclusively integrated short
vDNA substrates in concerted fashion (Valkov et al., 2009). These
results set the stage for the ensuing breakthrough.
Intasomes assembled with full-length wild-type PFV IN, Zn2+, and
pre-cleaved 19-mer vDNA substrate retained concerted integration
activity during prolonged storage in high salt containing buffers (Hare
et al., 2010a). A diffracting crystal form of the complex was identiﬁed
after over 40,000 crystallization trials, and its structure was initially
determined at 3.25 Å resolution. The PFV system has rather quickly
yielded 22 additional nucleoprotein complex structures that differ
from the basic Zn-IN-vDNA intasome through the presence of
biologically or pharmacologically-relevant ligands: Mn2+ or Mg2+
catalytic co-factor, tDNA, or INSTIs (Table 1).
In all PFV intasome crystal structures reported so far, the
asymmetric unit harbors an IN dimer (Fig. 5A, green and yellow)
bound to a single vDNA end, with only one of the monomers (green)
contacting the DNA. The trace of this molecule was continuous,
lacking electron density for just 9 and 18 N- and C-terminal residues,
respectively. By contrast only the CCD of the other IN chain was
discernable. The asymmetric nature of the dimer invokes compar-
ison to the HIV-1 reverse transcriptase p66/p51 heterodimer, where
two subunits adopt different tertiary structures despite harboring
similarly folded sub-domains (Jacobo-Molina et al., 1993; Kohlstaedt
et al., 1992). Although N-terminal extension domain (NED), NTD,
and CTD electron densities were missing for the outer PFV IN chain
(Fig. 5A, yellow), it seems unlikely this subunit would adopt the
same overall fold observed for the DNA-bound monomer. The
complete intasome is formed by a pair of symmetry related IN-vDNA
assemblies (Fig. 5B) (Hare et al., 2010a). The NTDs, CCDs, and CTDs
of the inner IN subunits formed intimate protein and DNA contacts
within the highly intertwined nucleoprotein complex. The NED, notstrictly essential for PFV IN activity in vitro (Pahl and Flügel, 1995;
Valkov et al., 2009) and not present in INs from most retroviral
genera, is involved in contacts with the vDNA backbone. As expected
from earlier analyses of 2-domain structures (Hare et al., 2009a;
Wang et al., 2001), the inner monomers of the PFV IN tetramer
(green and cyan) harbored the relevant active sites, the side chains
of their catalytic triad residues in close proximity to the reactive
vDNA 3′-hydroxyl (Fig. 6A). Concordantly, the NTD of each inner
monomer interacted in trans with a CCD from the opposing IN dimer
(Figs. 4C and 5B). The extended conformation of the DNA-bound IN
molecules was entirely novel, differing signiﬁcantly from previous
IN 2-domain structures (compare Fig. 5A with Figs. 3, 4A, and B). The
architecture of the PFV intasome was accordingly rather different
from previous HIV-1 IN tetramer-vDNA models built using prede-
cessor 2-domain structures as template (Chen et al., 2006, 2008; Gao
et al., 2001; Michel et al., 2009; Zhao et al., 2008). The familiar CCD
dimer interface was maintained in the structure, but occurred
between each outlier (yellow) and DNA-bound CCD, verifying that
only one active site per canonical CCD dimer was catalytically
competent (Fig. 5).
Soaking PFV intasome crystals in MnCl2 led to visualization of the
metal-bound intasomal active site at 2.55 Å resolution (Hare et al.,
2010a,b) (Fig. 6A). As predicted from prior work (Nowotny et al.,
2005; Steitz and Steitz, 1993), two metal ions were observed at each
functional site. Metal ion B, coordinated by the side chains of active
site residues Glu221 and Asp128, activates the 3′-OH vDNA
nucleophile for DNA strand transfer whereas metal ion A, coordi-
nated by Asp128 and Asp185, would destabilize the scissile tDNA
phosphodiester bond (Fig. 6A). The Tn5 transpososome was the
initial polynucleotidyl transferase CDC resolved by X-ray crystal-
lography (Davies et al., 2000) and despite lack of detectable
sequence homology between Tn5 transposase and PFV IN, their
DDE catalytic triads and associated metal ions superimposed
remarkably well (Hare et al., 2010a). Mg2+ could also be observed
at the PFV intasome active sites after soaking crystals with MgCl2,
though only position A was occupied (Hare et al., 2010a; S. Hare and
P. Cherepanov, unpublished observations). The presence of scissile
phosphodiester bonds during 3′ processing or DNA strand transfer
would supply additional ligands to, and predictably increase the
afﬁnity of, site B for Mg2+. Concordantly, INSTI-containing struc-
tures revealed two coordinated Mg2+ ions per inhibited active site
(Hare et al., 2010a,b).
Fig. 6. Wild type and S217H mutant intasome structures in committed and drug-bound forms elucidate the mechanism of INSTI action and basis for HIV-1 Q148H/R/K drug
resistance. (A) Mn-bound active site (PDB code 3OY9) revealed the coordination of two metal ions by the DDE catalytic triad (see main text for additional details). (B) RAL (yellow
scaffold) binding to an induced ﬁt pocket formed through interactions with coordinated metal ion (Mg2+) and the penultimate C16/G4 bp of the vDNA end ejects the terminal
adenine nucleotide (A17) and its afﬁliated 3′-OH nucleophile from the IN active site (PDB code 3OYA). (C) Superposition of wild-type intasome in committed (grey trace; same view
as panel A) and MK-2048 (magenta backbone) bound (blue trace; PDB code 3OYB) conformations. (D) Comparison of MK-2048-bound (PDB code 3OYL; blue trace) and unbound
S127H mutant (grey trace; PDB code 3OYK) intasome structures revealed signiﬁcant active site conformational changes (alterations in side chain positions indicated by arrows)
elicited by drug binding. Other labeling is the same as in Figs. 4 and 5.
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with the PFV intasome
Cell infection by PFV as well as PFV IN activity in vitro were
importantly sensitive to inhibition by RAL and the related INSTI
elvitegravir (EVG) (Valkov et al., 2009). Although INSTI scaffolds
are relatively diverse, they share two important chemical features
(reviewed in McColl and Chen, 2010). The ﬁrst is co-planar
heteroatoms (predominantly oxygen; otherwise nitrogen) pre-
dicted to chelate the crucial divalent metal ion pair in the IN active
site (Grobler et al., 2002). The second is halogenated benzyl
groups, postulated to bind within a hypothetical hydrophobic
pocket that formed upon intasome formation (McColl and Chen,
2010). As predicted, INSTI oxygen atoms interacted intimately
with bound metal ions at the IN active site (Hare et al., 2010a,b)
(Fig. 6, compare panel B to panel A). Gleaned from the crystal
structures, drug halobenzyl groups interacted with the penulti-
mate C/G base pair at the vDNA end, which effectively supplanted
the chemical moiety for the base of the vDNA 3′ adenosine and in
doing so ejected the nucleotide with its reactive 3′-OH from the
active site (Fig. 6B). The ejection of the 3′-OH nucleophile from the
active site forms the fundamental basis of INTSI action (Hare et al.,
2010a,b).HIV-1 resistance to RAL arises through one of three clinically-
relevant genetic pathways that are named for corresponding HIV-1
IN amino acid substitutions: Y143H/R/C, Q148H/R/K, and N155H
(Cooper et al., 2008; reviewed in McColl and Chen, 2010 and
Metiﬁot et al., 2010). Tyr143 in HIV-1 IN is analogous to PFV IN
Tyr212 (Valkov et al., 2009). Because the oxadiazole ring in RAL
stacks against the phenolic side chain of Tyr212 (Hare et al., 2010a)
(Fig. 6B), Y143H/R/C changes likely work by decreasing the afﬁnity
of the intasome–RAL interaction through alteration of the direct
drug binding contact. PFV IN residues Ser217 and Asn224 corre-
spond to HIV-1 residues Gln148 and Asn155, respectively (Valkov
et al., 2009). PFV IN mutant S217Q was viable in vitro and remained
sensitive to RAL inhibition whereas S217H IN activity displayed loss
of sensitivity to RAL and to a lesser extent to the second-generation
INSTI MK-2048 (Hare et al., 2010b). Intasome crystal structures
based on wild-type and S217H IN, with and without MK-2048,
suggested a mechanism of drug resistance for the predominant RAL
resistance Q148H/R/K pathway (Cooper et al., 2008). Ser217 sits at
the base of the active site (Figs. 6A–C). The bulky His substituent
slightly shifted the position of Asp185, which in turn precluded
metal binding to position A (Fig. 6D, grey trace and Mn ion). Binding
of MK-2048 to the wild-type intasome induced marginal active site
changes, primarily inﬂuencing Tyr212 position and to a lesser
Fig. 7. PFV IN TCC and STC crystal structures elucidate the mechanism of DNA strand transfer. (A) The PFV IN TCC structure highlighted the highly bent conformation of bound tDNA
(magenta and black strands), with the arrow indicating the spacing between scissile phosphodiester bonds (PDB code 3OS1). Red sticks, DDE side chains. (B) Themechanism of DNA
strand transfer elucidated by PFV IN CDC, TCC, and STC overlays (PDB codes 3OY9, 3OS1, and 3OS0, respectively). The dotted line represents the path taken by the adenosine 3′-OH
nucleophile during DNA strand transfer; the curved arrow highlights the rotation around the deoxyribose bond that displaces the newly formed vDNA-tDNA phosphodiester bond
from the enzyme active site. Color codes are as follows: magenta vDNA, CDC; grey tDNA, TCC; cyan vDNA and black tDNA, STC; green IN protein and DDE side chains, CDC; purple IN
ribbon and cyan DDE side chains, STC; grey metal ions, Mn2+ in CDC; black metal ion, position A in STC.
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in S217H IN backbone conformation were observed upon MK-2048
binding: the Cα atom of His217 for example was displaced by as
much as 1.1 Å (downward in Fig. 6D), destabilizing the local H-
bonding network (Fig. 6D, blue trace). Such a dramatic conforma-
tional change is likely to explain lowered drug binding afﬁnity and
hence lowered susceptibility of S217H IN to inhibition by MK-2048
and, due to the conserved mode of binding, all other INSTIs (Hare
et al., 2010b). The Q148H change in HIV-1 is routinely followed by
the secondary G140S mutation, which both restored inherent IN
catalytic function and increased RAL resistance (Delelis et al., 2009).
The analogous PFV IN residue is naturally serine, and the Ser209
side chain interestingly H-bonded with the mutant His side chain of
S217H (Fig. 6D). The G140S change in HIV-1 IN therefore likely
increases resistance by constraining the amount of movement
allowable for the mutant His148 side chain (Hare et al., 2010b).
These observations explain how Gln148 and Gly140 mutations are
likely to affect drug binding despite ﬁnding that neither residue
directly contacted RAL in a structure-based molecular model of the
HIV-1 intasome (Krishnan et al., 2010).
Engagement of tDNA by the intasome and mechanism of strand
transfer
Though integration occurs at numerous locations throughout
animal cell genomes, it is not entirely random with respect to local
DNA sequence at the site of insertion. As examples, HIV-1 preferen-
tially integrates at TDG↓GTWACCHA (Carteau et al., 1998; Holman and
Cofﬁn, 2005; Stevens and Grifﬁth, 1996;Wu et al., 2005) whereby PFV
favors TD↓VHDBHA (Trobridge et al., 2006; Valkov et al., 2009)
(arrows mark scissile phosphodiester bonds; underlines, tDNA
duplications — 5 bp for HIV-1 and 4 bp for PFV). Using idealized
synthetic tDNA constructs based on the in vitro PFV integration
consensus (Valkov et al., 2009), it was possible to co-crystallize the
PFV intasome with tDNA (Maertens et al., 2010). Blocking DNA strand
transfer by omitting divalent metal cations or by using vDNA lacking
the reactive 3′-OH allowed crystallization of the pre-catalytic TCC,
while crystals of the post-catalytic STC were obtained in the presence
of MgCl2 (Table 1).
The PFV intasome accommodated tDNA in a highly bent
conformation, with the major groove widened to 26.3 Å and the
minor groove compressed to 9.6 Å at the center of the integration site
(Maertens et al., 2010). This deformation allowed the intasomal active
sites, separated by as far as 26.5 Å, to access the scissile phosphodie-
ster bonds in tDNA (Fig. 7A). In the TCC and STC structures, tDNAbending is localized at the central base pair step, with a negative roll of
~60o. Rather impressively, such severe DNA kinking occurs in the
absence of direct protein-base stacking interactions. Accounting for
the overall aspeciﬁc nature of tDNA sequence preference during
integration, PFV IN–tDNA base interactions were relatively few. The
side chain of CTD residue Arg329 H-bonded with three residues in the
expanded major groove whereas CCD residue Ala188 made a van der
Waals contact with a minor groove base. Mutations of residues
analogous to Ala188 in ASLV (Ser124) and HIV-1 (Ser119) INs were
known to affect target site selection and/or strand transfer activity
(Harper et al., 2001; Nowak et al., 2009). Accordingly, PFV IN mutant
A188D was strand transfer defective, and the integration site
consensus of the A188S protein differed signiﬁcantly from the wild-
type (Maertens et al., 2010). Arg329 IN mutants (R329S and R329E)
led to even more drastic changes of the integration site consensus.
These results conﬁrmed that the observed side chain–base interac-
tions in the STC crystal structure in large part accounted for the
natural tDNA sequence preference of PFV integration (Maertens et al.,
2010). The crystallographic data also explained the preference for
distorted tDNA structures during retroviral integration (Katz et al.,
1998; Pruss et al., 1994; Pryciak and Varmus, 1992) and may account
for similar preferences among other polynucleotidyl transferase
superfamily members (Kuduvalli et al., 2001; Yanagihara and
Mizuuchi, 2002).
Overlaying metal-bound PFV IN CDC and TCC crystal structures
developed static snapshots of the DNA strand transfer reaction
mechanism. Metal ion B, coordinated by active site residues Asp128
and Glu221, positioned the vDNA 3′-OH nucleophile for in-line attack
of the tDNA scissile phosphodiester bond (Fig. 7B, dotted line). SN2
transesteriﬁcation reactions like DNA strand transfer are generally
reversible, but retroviruses rely on integration for functional gene
expression and their inheritance. The mechanistic basis for this
apparent paradox was elucidated by visualizing the TCC and STC
crystal structures together, as the newly formed vDNA-tDNA
phosphodiester bond was displaced from the STC IN active site by
2.3 Å due to an approximate 110° rotation of the corresponding
deoxyribose C4-C5 bond (Fig. 7B) (Maertens et al., 2010). The highly
distorted nature of bound tDNA likely imparts this dislocation to favor
the forward reaction product after integration.
Conclusions
The approximate 17-year history of retroviral IN structural biology
has witnessed piece meal accumulations of structures, starting from
individual HIV-1 IN domains and culminating inmultiple recent active
203X. Li et al. / Virology 411 (2011) 194–205PFV intasome nucleoprotein complexes. The entire retroviral integra-
tion pathway including the initial SSC has now been crystallized (Hare
et al., 2010a; Maertens et al., 2010) (S. Hare and P. Cherepanov,
unpublished results), revealing unprecedented details of intasome
assembly and IN reaction mechanisms. Despite these rather phenom-
enal advances, several questions in the ﬁeld of retroviral IN structural
biology remain to be answered. For examples, what are the roles of
the outer IN domains “missing” in the current PFV structures? We
infer these elements are unlikely to interact with vDNA or tDNA and
by extension that they, like the observable outer CCDs, play
supportive structural roles in intasome function. A somewhat related
question is the physiological relevance of non-DNA bound IN
structures. The intasome is comprised of four IN monomers, yet
approximately 50 to 100 IN molecules package into each virion
(Swanstrom and Wills, 1997). Although the complement of IN
molecules in ensuing reverse transcription and preintegration
complex replication intermediates is unknown, stoichiometry is likely
to exceed the four molecules required for integration. Numerous
cellular factors have been shown to interact with IN proteins (Turlure
et al., 2004; Van Maele et al., 2006) and some of these, for example
karyopherin proteins, could potentially function via interacting with
DNA-free IN structures. Also unanswered is the structural role of the
IN C-terminal tail (Fig. 1), missing from all structures (Chen, J.C. et al.,
2000; Z. Chen, et al., 2000; Hare et al., 2010a; Yang et al., 2000) yet
critical for HIV-1 IN function (Dar et al., 2009).
Another important area of research is obtaining structures for
additional retroviral intasomes. Though ‘humanized’ versions of PFV
IN like S217Q and S217H behaved similarly in vitro to their HIV-1
counterparts, the ability to substitute PFV IN mutants for important
HIV-1 IN drug resistance changes will have its limits (Hare et al.,
2010b). Given the relative degrees of amino acid sequence and
structural homology among IN proteins (Johnson et al., 1986;
Engelman and Craigie, 1992; Hare et al., 2009a, 2010a), we anticipate
all retroviral intasomes will assume the basic architecture elucidated
for PFV, but this has yet to be demonstrated. Considerable variation in
interdomain linker lengths among IN proteins (Fig. 1) for example
suggests potential constraints on assembled quaternary structures.
Recent PFV intasome-based constructions of HIV-1 molecular models
(Krishnan et al., 2010; Tang et al., 2010) and subsequent validation of
novel IN-vDNA contacts (Krishnan et al., 2010) for the time being are
consistent with a retroviral family-wide scaffold. Short of solving 3-
dimensional structures of active HIV intasomes, such models are
expected to signiﬁcantly impact INSTI development moving forward.
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